Vera Therapeutics, Inc.
Vera Therapeutics, Inc. (VERA): 1 pipeline candidate · 1 upcoming catalyst · ~16 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
16.3 months
D/E 0.24
Lead: Phase 2
1 candidate
1 upcoming, next in ~744d
0 buys · 12 sells (180d)
A transparent, data-derived signal for Vera Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.4B
Cash
$114.4M
Quarterly Burn
$106.5M
Runway
16.3 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| Atacicept | Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
228
Total value held
$2.44B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 5,367,214 | $215.9M |
| blackrock, inc. | 5,088,102 | $204.7M |
| deep track capital, lp | 4,106,067 | $165.2M |
| deerfield management company, l.p. | 3,722,100 | $149.7M |
| state street corp | 3,363,638 | $135.3M |
| fmr llc | 2,676,422 | $107.7M |
| eversept partners, lp | 2,173,286 | $87.4M |
| woodline partners lp | 2,002,074 | $80.5M |
| bellevue group ag | 1,710,771 | $68.8M |
| alliancebernstein l.p. | 1,314,242 | $66.6M |
Showing top 10 of 228 institutional holders of Vera Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Vera Therapeutics, Inc.'s pipeline?
Vera Therapeutics, Inc. (VERA) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Vera Therapeutics, Inc.'s lead drug candidate?
Vera Therapeutics, Inc.'s most advanced tracked candidate is Atacicept (Phase 2) for IgA Nephropathy (IgAN); Lupus Nephritis (LN); pMN.
What is Vera Therapeutics, Inc.'s next catalyst?
Vera Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effic" — expected July 1, 2028.
What is Vera Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Vera Therapeutics, Inc. has approximately 16.3 months of cash runway.
What is Vera Therapeutics, Inc.'s market capitalization?
Vera Therapeutics, Inc.'s market capitalization is approximately $2.4B.
Get the full picture on Vera Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.